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Background. The treatment of keloids and hypertrophic scars has been difficult and a 
recent French study showed that bleomycin has been useful in the treatment of these 
lesions. 
Objective. To determine the effectiveness and safety of bleomycin in the treatment of 
hypertrophic scars and keloids when this drug is administered through multiple 
superficial punctures. 
Methods. We applied bleomycin to keloids and hypertrophic scars in 13 patients using 
a multiple-puncture method on the surface of the skin. All patients were given 
bleomycin at a concentration of 1.5 IU/ml. Clinical response after treatment was 
classified according to the following scale: complete flattening (100%), highly 
significant flattening (>90%), or significant flattening (75–90%). 
Results. The clinical response was very positive in all cases: complete flattening in six 
cases, highly significant flattening in six cases, and significant flattening in one case. 
Two patients presented a recurrence as a small nodule 10 and 12 months after the last 
infiltration. 
Conclusions. These clinical findings show that administration of bleomycin in keloids 
and hypertrophic scars shows promise and needs further investigation. 
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Keloids and hypertrophic scars are two kinds of abnormal scar formation in the skin.1–3 
At the present time, the mechanism that causes them is not fully understood, but it is 
thought to involve local histologic factors in connection with a hereditary component in 
most cases. Today there are many ways of treating these conditions with different 
responses.1–3 Corticosteroids administered intralesionally have been useful in keloids 
and hypertrophic scars. Topically applied silicones or gel sheets are sometimes a good 
treatment. Other treatments include cryotherapy alone or in combination with 
intralesional corticosteroids, intralesional 5-fluorouracil (5-FU), interferons, surgery, 
and lasers. Recently a French study in 36 patients showed that bleomycin can be useful 
for these lesions. However, these procedures sometimes pose therapeutic problems: (1) 
the forms of treatment available at present are not effective in all cases; (2) their use is 
long term and sometimes lesions reappear when treatment is suspended; and (3) the 
recommended treatment occasionally requires very aggressive measures that are quite 
disproportionate to the benign character of the lesions. 
In this study we present our experience of treating 13 patients with keloids or 
hypertrophic scars with bleomycin. In all cases the lesions cleared completely or almost 
completely. To this we must add that the drug is easy to administer, moderately priced, 
and almost free of side effects. 
 
 
 
MATERIALS AND METHODS 
 
In this study we included 13 patients, 10 female and 3 male, ages 14–36 years. In three 
cases the lesions were on the shoulder, one on the back, three in the presternal region, 
four at various different sites, one on the chin, and one on the face (Figures 1–3). In all 
cases the lesions were accompanied by local pruritus. The lesions had been present for 2 
months to several years, and were secondary to surgery (five patients), of spontaneous 
origin (three patients), caused by vaccination (two patients) or by acne (two patients), or 
the result of accidental cuts (one patient) (Table 1). In seven of the patients no previous 
treatment had been given. All patients gave verbal consent before we used bleomycin, 
and female patients were warned not to become pregnant during treatment. 
We analyzed the Fitzpatrick skin type in each patient.4 We followed other authors5 in 
our definitions of hypertrophic scars and keloids: hypertrophic scars can flatten 
spontaneously in the course of one or several years; keloids persist and may even extend 
beyond the site of the original injury. 
The same method was used in all 13 patients. First, the lesion was anesthetized with 
intralesional 2% mepivacaine injection. After that the bleomycin was dripped onto the 
lesion, and then multiple punctures were made on the lesions by means of a syringe and 
a 25-gauge 5/8 0.5 X 16 needle. This technique is different than that used by Shelley 
and Shelley;6 these authors first drizzled the bleomycin solution onto the wart and then 
punctured it with a bifurcated beveled vaccination needle. Our technique ensured that 
only a very small quantity of bleomycin penetrated into the lesion. In each case the 
maximum dose applied was 2 cm3/cm2 of skin treated, at a concentration of 1.5 IU/ml, 
and a maximum of 6 cm3 of bleomycin was given per session. We used a pattern of 40 
punctures/5 mm2. 
Sessions were held 1–4 months apart. At the present time, one to five sessions have 
been given to different patients (Table 1). The number of sessions was established for 
each patient depending on the cosmetic and functional posttreatment situations. Each 
patient was assessed before bleomycin treatment for four clinical points by anamnesis 
and clinical examination: size, symptomatic improvement, color, and thickness of 
keloids or hypertrophic scars. In addition, other side effects such as hepatic dysfunction 
were evaluated after four sessions of bleomycin by hepatic biochemistry. The 
information was recorded in the medical records. In all cases the following scale for 
assessing the results of treatment was used at the end of treatment: complete flattening 
of the lesion (100%), highly significant flattening (>90%), or significant flattening (75–
90%). We defined recurrence as local relapsing in patients who had obtained previous 
complete flattening. We explain side effects and the time of recurrence in the Results 
section. All patients were evaluated by the same person (A.E.). 
 
 
RESULTS 
 
The results of the 13 patients are shown in Table 1. Six of them presented hypertrophic 
scars and seven presented keloids. Four patients were skin type II and nine patients were 
skin type III. 
In all patients, pruritus disappeared after the first session. No side effects, except slight 
residual pigmentation in two patients with skin type III (patients 2 and 8), were 
observed. In seven patients, treatment was concluded after complete flattening had been 
achieved (patients 1–4, 8, 11, and 13) (53.8%) after 2, 5, 3, 3, 4, 1, and 3 sessions, 
respectively (Figure 1B). Four of the seven patients had hypertrophic scars and three 
had keloids. Two of the three patients with keloids (patients 2 and 8; Figure 2B) 
presented with a small nodule 12 and 10 months, respectively, after the last infiltration. 
The other complete flattening patients have so far presented no recurrence of the lesion 
and are stable 11 months and 3 years after bleomycin treatment. Highly significant 
flattening (>90%) was achieved in another five patients (patients 6, 7, 9, 10, and 12) 
(38.4%) (Figure 3B) and has endured for 5 months–2 years. Four of these five patients 
had keloids and only one had hypertrophic scars. In one patient we obtained significant 
flattening (patient 5); the patient found this to be aesthetically satisfactory and decided 
to discontinue treatment. This improvement is stable 8 months after treatment. This 
patient had hypertrophic scars (Table 1). 
 
 
DISCUSSION 
 
Hypertrophic scars and keloids are abnormal growths of the connective tissue secondary 
to trauma of the skin, the origin of which is usually apparent. While in the latter the 
connective tissue spreads beyond the damaged area, in hypertrophic scars it is confined 
to the site of the trauma.1–3,5 Many times it is almost impossible to distinguish between 
the two entities histologically, although in hypertrophic scars the abnormalities tend to 
clear up earlier.5
In recent years, various studies have clarified the mechanism by which connective tissue 
forms in normal and pathologic situations.7 These studies have shown that formation of 
scar tissue in wounds produces an increase in the lysyl-oxidase enzyme, which triggers 
cross-linking of the aldehyde groups derived from the lysin amino acids, thus fomenting 
the maturation of collagen.7–9 This enzyme is located outside the cells along the 
collagen and elastin fibers, and inside the cells in fibroblasts, endothelial cells, sweat 
and sebaceous glands, the erector pili muscle, and in some keratinocytes.10 
Concentrations of this have been found to be normal or raised in keloid and 
hypertrophic scars,11 and increased in some conditions which involve heightened 
collagen synthesis.12 Moreover, in keloid and hypertrophic scars other abnormalities 
have been detected, such as an increase in water, calcium, fibronectin, collagen type VI, 
and transforming growth factor (TGF)-β1, certain enzymes such as proline hydroxylase 
and galactosylhydroxylysyl glucosyltransferase, and cross-linking in the collagen that is 
formed; a decrease in polypeptides of protocollagen as a result of an increase in 
degradation; and concentrations of collagenase and collagen I and III which vary in 
different studies.13
Bleomycin administration has proved useful in certain malignancies.14 It has also been 
effective in the treatment of keratoacanthomas,15 cutaneous neurofibromas,16 and 
recalcitrant vulgar warts.17 More recently, intradermal bleomycin injections have been 
shown to bring about significant improvements in keloid and hypertrophic scars.18 In 
this French study they treated 31 keloids and 5 hypertrophic scars with three to five 
intralesional infiltrations within a 1-month period. They obtained a total regression of 
84%. They observed that the treatment was effective in all cases within the first two 
infiltrations, evidenced by a reduction in the volume of keloid, a clear reduction of 
functional impairment in most patients. In addition, injection of bleomycin in the skin of 
healthy subjects has been found histologically to cause necrosis of keratinocytes with a 
mixed inflammatory infiltrate, together with the expression of various adhesion 
molecules.19 Furthermore, in common warts treated with bleomycin, apoptoic cells also 
appear.20 Despite these findings, however, the mechanism by which this drug acts is not 
entirely clear. 
One of the best-known side effects of bleomycin is pulmonary, renal, and cutaneous 
fibrosis when the drug is administered systemically.21 This, together with the 
observation of scleroderma-like manifestations secondary to bleomycin,22 would seem 
to be in contradiction to the clinical effect observed in our patients. Studies of the 
mechanism of drug action in these cases have yielded contradictory results. 
Administration of bleomycin in rats produces an increase in protocollagen and lysyl-
oxidase synthesis in the lungs and in fibroblasts in the dermis.23–26 But other recent 
studies have pointed out that in cultures of human dermal fibroblasts there is a highly 
significant reduction in lysyl-oxidase as a result of the action of bleomycin.27 Similarly 
the administration of various cytostatics such as bleomycin has been found to produce 
inhibition of the collagen synthesis when its effect is analyzed in cultures of human 
dermal fibroblasts. If TGF-β1 is added to the culture, bleomycin also inhibits the 
collagen synthesis resulting from this growth factor.28
We are aware of the limitations of this study since we did not use a control group. We 
cannot know with any degree of certainty what mechanism caused these lesions to 
improve in our patients. Nevertheless, we think that improvement could be the result of 
a reduction in collagen synthesis and/or an increase in its destruction, or due to 
inhibition of lysyl-oxidase or TGF-β1. In addition, we believe that bleomycin, 
administered through multiple intralesional punctures as we have described, is an 
effective treatment for keloid and hypertrophic scars. As Shelley and Shelley6 described 
in the case of common warts, this means of applying bleomycin ensures safety, as far 
less (probably under 5%) penetrates through to the bloodstream than when the drug is 
given intradermally. 
In summary, we think bleomycin may be a drug of promise in the treatment of keloids 
and hypertrophic scars using multiple needle puncture. Nevertheless, further studies will 
provide more information about the mechanism by which this drug acts in this type of 
lesion. 
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Figure 1. Patient 4. A) Keloid lesion on the back after extirpation of a nevus. B) 
Complete disappearance, with no recurrence at 11 months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Patient 2. A) Keloid after vaccination in the deltoid region. B) Complete 
healing of the lesion, with one small recurrence (arrow) 1 year after the end of 
treatment. 
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Figure 3. Patient 6. A) Multiple keloid lesions. The original lesion had been in the 
presternal region. B) Almost complete disappearance (>90%). The patient remains 
stable at 10 months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 1. Patient Characteristics 
Patient Sex Age (years) 
Skin 
type 
Type of 
scar Localizations
Time of 
course 
Treatment 
before 
No. of 
sessions Trigger factor Side effects 
Results 
after 
treatment 
Evolution 
No lesion after 16 
months 1 F 23 II HS Chain 2 months Corticosteroids 2 Surgery No CF 
2 F 19 III KL Shoulder 12 months No treatment 5 Vaccination Hyperpigmentation CF
a Small nodule after 
1 year 
3 F 36 III KL Shoulder Several years Corticosteroids 3 Vaccination No CF 
No lesion after 3 
years 
No lesion after 11 
months 4 F 14 III HS Back 9 months No treatment 3 Surgery No CF 
No growing back 
after 8 months 5 F 35 II HS Shoulder 7 months Thiomucase 2 Surgery No SF 
No growing back 
after 10 months 6 F 23 III KL 
Multiple 
localization 6 years No treatment 2 Spontaneous No HSF 
7 F 21 II KL Multiple localization 5 years Corticosteroids 3 Spontaneous No HSF 
No growing back 
after 10 months 
Small nodules 
after 10 months 8 M 30 III KL Chest 3 years Silicone 4 Acne Hyperpigmentation CF
a
9 F 27 III KL Multiple localization 
Several 
years Corticosteroids 4 Spontaneous No HSF 
No lesion after 5 
months 
No lesion after 2 
years 10 F 27 II HS Chest 6 months No treatment 2 Surgery No HSF 
No lesion after 13 
months 11 F 18 III HS Chest 5 months No treatment 1 Surgery No CF 
12 M 17 III KL Multiple localization 
12 
months No treatment 2 Acne No HSF 
No growing back 
after 7 months 
No lesion after 1 
year 13 M 20 III HS Face 2 years No treatment 3 Cut No CF 
F: female; M: male; KL: keloids; HS: hypertrophic scars; CF: complete flattening; HSF: highly significant flattening; SF: significant flattening. aPatients with relapsing. 
